Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Palmitoleic (16:1 n-7) acid and metabolic health: integrating observational, clinical, and mechanistic evidence

Destaillats F., Oliveira M., Zhou X., Correa M., Lippmeier JC., Parker L.

Narrative Review on Type 2 Diabetes, published in Front Nutr (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Nutr (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42245547
PMCID
PMC13230081
DOI
10.3389/fnut.2026.1801946

Abstract (original English)

Palmitoleic acid (POA; 16:1 n-7) has been proposed as a lipokine linking adipose tissue, liver, and skeletal muscle metabolism, but its relevance to human metabolic health remains uncertain. This narrative review integrates observational, clinical, and mechanistic evidence across circulating lipids and lipoproteins, glucose homeostasis, inflammation and vascular markers, adiposity, and hepatic endpoints. In observational studies, higher POA in esterified lipid fractions often tracks with de novo lipogenesis, hypertriglyceridemia, adiposity, insulin resistance, and fatty liver, whereas findings for free POA are more heterogeneous. In human interventions, POA-rich food matrices such as macadamia-based diets can improve LDL-cholesterol and related ratios when they replace saturated fat, but these studies do not isolate the specific contribution of POA from the broader monounsaturated-fat matrix. By contrast, short-term trials of purified POA supplementation have largely reported neutral effects on standard fasting lipids, glycemic markers, and inflammatory biomarkers. Pre-clinical and in vitro studies support biological plausibility, with reported effects on insulin signaling, hepatic lipid metabolism, adipose remodeling, and inflammatory pathways. Overall, current evidence supports cautious interpretation: POA is biologically interesting, but clinically meaningful benefits of pur

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research